Aclidinium bromide/formoterol

What Is aclidinium bromide and formoterol fumarte ?[edit]

Aclidinium bromide and formoterol fumarte powder (Duaklir Pressair) is a combination of aclidinium bromide an anticholinergic, and formoterol fumarate, a long-acting beta2-adrenergic agonist (LABA).

This combination combination of aclidinium bromide (an anticholinergic) and formoterol fumarate (a LABA) indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Duaklir Pressair contains two bronchodilators: aclidinium a long-acting muscarinic antagonist (also known as an anticholinergic) and formoterol a long-acting beta2-adrenergic agonist.

This medicine cannot be used in:

In patients with Severe hypersensitivity to milk proteins
In patients with hypersensitivity to aclidinium bromide, formoterol fumarate, or to any component of the product

The recommended dose of this medicine is one oral inhalation of 400 mcg/12 mcg, twice daily (once in the morning and once in the evening).
Do not take more than one inhalation twice daily.

This medicine is available in fallowing doasage form:

This combination is available as inhalation Powder
It is a breath-actuated multi-dose dry powder inhaler metering 400 mcg of aclidinium bromide and 12 mcg of formoterol fumarate per actuation.

Common possible side effects of this medicine include:

Possible serious side effects, may include:

Do not initiate to treat acute symptoms of COPD
Do not use in combination with an additional medicine containing a LABA because of risk of overdose.
If paradoxical bronchospasm occurs, discontinue the medication and institute alternative therapy.
Use with caution in patients with cardiovascular disorders.
Use with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus and ketoacidosis.
Always be alert with hypokalemia and hyperglycemia.
Use with caution in patients with narrow-angle glaucoma.
Worsening urinary retention may occur with this medication.

The most common symptoms of overdosage include blurred vision, dry mouth, nausea, muscle spasms, tremor, headache, palpitations, and systolic hypertension.
Treatment of overdosage consists of discontinuation of Duaklir Pressair together with institution of appropriate symptomatic and/or supportive therapy.

There are no adequate and well-controlled studies of Duaklir Pressair or its individual components, formoterol fumarate or aclidinium bromide, in pregnant women.

This medication is not indicated for use in children.
The safety and effectiveness of Duaklir Pressair in the pediatric population have not been established.

Store Duaklir Pressair in a dry place at 20°C-25°C (68°F-77°F); excursions permitted to 15-30°C (59-86°F) .
Do not store the inhaler on a vibrating surface.
The Pressair inhaler should be stored inside the sealed bag and only be opened immediately before use.
Throw away the bag and the desiccant sachet.
Throw away (dispose of) the Pressair inhaler after the marking “0” with a red background shows in the middle of the dose indicator, when the device is empty and locks out, or 2 months after the date you opened the sealed bag that the inhaler comes in, whichever comes first.
Keep out of reach of children.

This drug article relating to the respiratory system is a stub. You can help WikiMD by expanding the page.

This medical article is a stub. You can help WikiMD by expanding the page.